General Information:

Id: 1,989 (click here to show other Interactions for entry)
Diseases: Cardiovascular disease
Diabetes mellitus, type II - [OMIM]
Insulin resistance
Myocardial infarction - [OMIM]
Nephropathy, diabetic
Neuropathy, diabetic
Retinopathy, diabetic
Stroke, ischemic - [OMIM]
Reference: Lardizabal JA and Deedwania PC(2010) The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus Curr Cardiol Rep 12: 464-471 [PMID: 20809236]

Interaction Information:

Comment ACE catalyzes the conversion of angiotensin I to AT II, increasing the levels of circulating AT II. Being biochemically identical to the kininase II enzyme, ACE also promotes the degradation of bradykinin, leading to reductions in both bradykinin and NO levels. Treatment with ACEI agents, by blocking the actions of ACE, causes reduction in the levels of AT II, as well as increase in the levels of bradykinin and NO, which results not only in vasodilatation but also enhanced insulin insensitivity and improved cellular glucose uptake.
Formal Description
Interaction-ID: 15673



increases_quantity of


Angiotensin II

Drugbank entries Show/Hide entries for ACE